Biontech Se Spon Ads Each Rep 1 Ord Shs (BNTX) Stock
German biotech company developing mRNA vaccines and cancer treatments. Here's the price, business snapshot, and what's worth knowing about Biontech Se Spon Ads Each Rep 1 Ord Shs in October 2026.
BioNTech SE (BNTX) is a Germany-based biotechnology company known for its mRNA platform and as a co-developer of the Comirnaty COVID-19 vaccine with Pfizer. With a market capitalisation around $25.2 billion, BioNTech combines infectious-disease programmes with an expanding oncology pipeline that includes personalised cancer vaccines and other immunotherapies. Investors should note that the company’s recent revenues were materially bolstered by pandemic vaccine sales, which may be cyclical as public-health demand shifts. BioNTech is R&D intensive, requiring significant spending and clinical progress to unlock long-term value; regulatory approvals, trial outcomes and competition from other vaccine and cancer-therapy developers are key catalysts and risks. Strategic partnerships and manufacturing scale are strengths, but the share price can be volatile. This is general educational information, not investment advice — prospective investors should consider their risk tolerance and seek personalised advice.
Why It’s Moving
BioNTech Faces Operational Shakeup and Analyst Scrutiny Amid Pipeline Volatility
- The company confirmed it will shutter sites in Germany and Singapore because no buyers emerged for its pandemic-era manufacturing infrastructure.
- BMO Capital Markets recently downgraded the stock and lowered price targets after BioNTech reduced its 2027 guidance and faced a colorectal cancer vaccine setback.
- Investors are weighing the negative operational news against a recent lung cancer clinical success, which analysts suggest highlights the potential value of the company's deep pipeline.
BioNTech Faces Operational Shakeup and Analyst Scrutiny Amid Pipeline Volatility
- The company confirmed it will shutter sites in Germany and Singapore because no buyers emerged for its pandemic-era manufacturing infrastructure.
- BMO Capital Markets recently downgraded the stock and lowered price targets after BioNTech reduced its 2027 guidance and faced a colorectal cancer vaccine setback.
- Investors are weighing the negative operational news against a recent lung cancer clinical success, which analysts suggest highlights the potential value of the company's deep pipeline.
Sixth Month Growth Performance
When is the next earnings date for BIONTECH SE SPON ADS EACH REP 1 ORD SHS (BNTX)?
BioNTech has not yet announced a confirmed date for its next earnings release. Based on the company's historical reporting pattern of releasing results approximately three months after the previous quarter, the upcoming report is expected in early November 2026. This scheduled disclosure will cover financial performance for the third quarter of fiscal year 2026. Investors should monitor official communications for the precise confirmation of this anticipated timeline.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying BioNTech's stock with a target price of $120.88, indicating growth potential.
Financial Health
BioNTech is performing well with strong revenue, profit margins, and cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
mRNA platform potential
The mRNA approach underpins vaccines and new therapeutics, offering scalability and adaptability, though clinical success and commercial demand can vary.
Oncology pipeline progress
BioNTech’s cancer programmes, including personalised vaccines, could be long-term value drivers if trials succeed, but outcomes and timelines are uncertain.
Partnerships and scale
Collaborations—most notably with Pfizer—boost manufacturing reach and revenue potential, though reliance on partners and market shifts present risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
